Kent Lake Capital’s Starling Oncology Warrant STLNW Stock Holding History
Bought
Maintained
Sold
Other funds holding STLNW
DM
HCM
UOC
DKCM
MF
KC
RCM
USPCM
Kent Lake Capital's STLNW Position: Q3 2021 in Review
Kent Lake Capital sold out of Starling Oncology Warrant (STLNW) in Q3 2021, closing a stake of 36,280 shares — an estimated $63K sold.
Kent Lake Capital first reported a position in STLNW in Q1 2021 and held it in 2 quarters. The position peaked at $63K in Q2 2021. 21 funds tracked by Wall St. Rank hold STLNW as of Q3 2021.
- Kent Lake Capital reported no remaining Starling Oncology Warrant position as of Q3 2021 after selling out during the quarter.
- Kent Lake Capital sold 36,280 Starling Oncology Warrant shares in Q3 2021, an estimated $63K.
- Kent Lake Capital first reported a position in Starling Oncology Warrant in Q1 2021 and held it in 2 quarters.
- Kent Lake Capital's Starling Oncology Warrant position peaked at $63K in Q2 2021.
- 21 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q3 2021.
Based on Kent Lake Capital's 13F filing for Q3 2021, filed 15 Nov 2021.